Published in Biochem J on June 01, 1995
Homophilic complex formation of MT1-MMP facilitates proMMP-2 activation on the cell surface and promotes tumor cell invasion. EMBO J (2001) 2.23
TIMP-2 is required for efficient activation of proMMP-2 in vivo. J Biol Chem (2000) 2.00
Control of type IV collagenase activity by components of the urokinase-plasmin system: a regulatory mechanism with cell-bound reactants. EMBO J (1997) 1.85
Selective modulation of matrix metalloproteinase 9 (MMP-9) functions via exosite inhibition. J Biol Chem (2008) 1.15
Differentiation of secreted and membrane-type matrix metalloproteinase activities based on substitutions and interruptions of triple-helical sequences. Biochemistry (2007) 1.05
High throughput screening of potentially selective MMP-13 exosite inhibitors utilizing a triple-helical FRET substrate. Bioorg Med Chem (2008) 1.03
Exosite interactions impact matrix metalloproteinase collagen specificities. J Biol Chem (2011) 1.02
Expression of matrix metalloprotease-2-cleaved laminin-5 in breast remodeling stimulated by sex steroids. Am J Pathol (1999) 1.01
Triple-helical transition state analogues: a new class of selective matrix metalloproteinase inhibitors. J Am Chem Soc (2007) 1.00
The C-terminal domains of ADAMTS-4 and ADAMTS-5 promote association with N-TIMP-3. Matrix Biol (2009) 0.97
Characterization of structural determinants and molecular mechanisms involved in pro-stromelysin-3 activation by 4-aminophenylmercuric acetate and furin-type convertases. Biochem J (1996) 0.95
Active MMP-2 effectively identifies the presence of colorectal cancer. Int J Cancer (2009) 0.92
Involvement of a region near valine-69 of tissue inhibitor of metalloproteinases (TIMP)-1 in the interaction with matrix metalloproteinase 3 (stromelysin 1). Biochem J (1997) 0.89
Expression of matrix metalloproteinases in the subretinal fluid correlates with the extent of rhegmatogenous retinal detachment. Graefes Arch Clin Exp Ophthalmol (2006) 0.86
Functional proteomic analysis of seminal plasma proteins in men with various semen parameters. Reprod Biol Endocrinol (2013) 0.82
Hepatocyte produced matrix metalloproteinases are regulated by CD147 in liver fibrogenesis. PLoS One (2014) 0.80
Enhancement of membrane-type 1-matrix metalloproteinase (MT1-MMP) production and sequential activation of progelatinase A on human squamous carcinoma cells co-cultured with human dermal fibroblasts. Br J Cancer (1999) 0.80
Optimization of total protein and activity assays for the detection of MMP-12 in induced human sputum. BMC Pulm Med (2010) 0.78
Active matrix metalloproteinase-2 activity discriminates colonic mucosa, adenomas with and without high-grade dysplasia, and cancers. Hum Pathol (2011) 0.76
Expression of soluble and functional full-length human matrix metalloproteinase-2 in Escherichia coli. J Biotechnol (2011) 0.76
Collagenolytic Matrix Metalloproteinase Activities toward Peptomeric Triple-Helical Substrates. Biochemistry (2015) 0.76
The Influence of Differentially Expressed Tissue-Type Plasminogen Activator in Experimental Autoimmune Encephalomyelitis: Implications for Multiple Sclerosis. PLoS One (2016) 0.75
KLK6 proteolysis is implicated in the turnover and uptake of extracellular alpha-synuclein species. Oncotarget (2016) 0.75
Sequence from picomole quantities of proteins electroblotted onto polyvinylidene difluoride membranes. J Biol Chem (1987) 34.69
A matrix metalloproteinase expressed on the surface of invasive tumour cells. Nature (1994) 9.31
Matrix metalloproteinases: a review. Crit Rev Oral Biol Med (1993) 9.03
Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J (1991) 8.29
Tumor cell interactions with the extracellular matrix during invasion and metastasis. Annu Rev Cell Biol (1993) 6.53
The interaction of alpha 2-macroglobulin with proteinases. Characteristics and specificity of the reaction, and a hypothesis concerning its molecular mechanism. Biochem J (1973) 5.99
Autoradiography using storage phosphor technology. Electrophoresis (1990) 4.61
The cysteine switch: a principle of regulation of metalloproteinase activity with potential applicability to the entire matrix metalloproteinase gene family. Proc Natl Acad Sci U S A (1990) 4.46
H-ras oncogene-transformed human bronchial epithelial cells (TBE-1) secrete a single metalloprotease capable of degrading basement membrane collagen. J Biol Chem (1988) 4.06
Biochemical and immunological characterization of the secreted forms of human neutrophil gelatinase. J Biol Chem (1985) 3.15
Tissue inhibitor of metalloproteinase (TIMP-2). A new member of the metalloproteinase inhibitor family. J Biol Chem (1989) 2.87
Multiple modes of activation of latent human fibroblast collagenase: evidence for the role of a Cys73 active-site zinc complex in latency and a "cysteine switch" mechanism for activation. Proc Natl Acad Sci U S A (1990) 2.68
A metalloproteinase from human rheumatoid synovial fibroblasts that digests connective tissue matrix components. Purification and characterization. J Biol Chem (1986) 2.65
Matrix metalloproteinase 3 (stromelysin) activates the precursor for the human matrix metalloproteinase 9. J Biol Chem (1992) 2.43
Independent expression and cellular processing of Mr 72,000 type IV collagenase and interstitial collagenase in human tumorigenic cell lines. Cancer Res (1990) 2.40
An endopeptidase from rheumatoid synovial tissue culture. Biochim Biophys Acta (1972) 2.25
Matrix metalloproteinase 2 from human rheumatoid synovial fibroblasts. Purification and activation of the precursor and enzymic properties. Eur J Biochem (1990) 2.13
Human 72-kilodalton type IV collagenase forms a complex with a tissue inhibitor of metalloproteases designated TIMP-2. Proc Natl Acad Sci U S A (1989) 2.12
The interglobular domain of cartilage aggrecan is cleaved by PUMP, gelatinases, and cathepsin B. J Biol Chem (1992) 1.85
Plasma membrane-dependent activation of the 72-kDa type IV collagenase is prevented by complex formation with TIMP-2. J Biol Chem (1993) 1.83
The activation of human type IV collagenase proenzyme. Sequence identification of the major conversion product following organomercurial activation. J Biol Chem (1989) 1.80
Alpha 2-macroglobulin. Methods Enzymol (1981) 1.55
The C-terminal domain of 72 kDa gelatinase A is not required for catalysis, but is essential for membrane activation and modulates interactions with tissue inhibitors of metalloproteinases. Biochem J (1992) 1.49
Differential roles for two gelatinolytic enzymes of the matrix metalloproteinase family in the remodelling cornea. Dev Biol (1991) 1.41
Domain structure of human 72-kDa gelatinase/type IV collagenase. Characterization of proteolytic activity and identification of the tissue inhibitor of metalloproteinase-2 (TIMP-2) binding regions. J Biol Chem (1992) 1.40
Regulation of the autoactivation of human 72-kDa progelatinase by tissue inhibitor of metalloproteinases-2. J Biol Chem (1991) 1.40
The activity of the tissue inhibitors of metalloproteinases is regulated by C-terminal domain interactions: a kinetic analysis of the inhibition of gelatinase A. Biochemistry (1993) 1.36
Tissue inhibitor of metalloproteinases-2 inhibits the activation of 72 kDa progelatinase by fibroblast membranes. Biochim Biophys Acta (1991) 1.28
Purification and characterization of matrix metalloproteinase 9 from U937 monocytic leukaemia and HT1080 fibrosarcoma cells. Biochem J (1992) 1.27
Evidence that human rheumatoid synovial matrix metalloproteinase 3 is an endogenous activator of procollagenase. Arch Biochem Biophys (1988) 1.24
Binding of tissue inhibitor of metalloproteinases 2 to two distinct sites on human 72-kDa gelatinase. Identification of a stabilization site. J Biol Chem (1991) 1.19
Human progelatinase A can be activated by matrilysin. FEBS Lett (1994) 1.10
The complex between a tissue inhibitor of metalloproteinases (TIMP-2) and 72-kDa progelatinase is a metalloproteinase inhibitor. Eur J Biochem (1991) 1.08
Expression of human recombinant 72 kDa gelatinase and tissue inhibitor of metalloproteinase-2 (TIMP-2): characterization of complex and free enzyme. Biochem J (1993) 1.01
Higher-order complex formation between the 72-kilodalton type IV collagenase and tissue inhibitor of metalloproteinases-2. Biochemistry (1992) 0.97
Matrix metalloproteinases cleave at two distinct sites on human cartilage link protein. Biochem J (1993) 0.96
Disruption of the cysteine-75 and zinc ion coordination is not sufficient to activate the precursor of human matrix metalloproteinase 3 (stromelysin 1). Biochemistry (1993) 0.94
Metalloproteinase domain structure, cellular invasion and metastasis. Biochem Soc Trans (1994) 0.93
Activation of TIMP-2/progelatinase A complex by stromelysin. Biochem Biophys Res Commun (1992) 0.84
Activity of ternary gelatinase A-TIMP-2-matrix metallo-proteinase complexes. Biol Chem Hoppe Seyler (1994) 0.84
Morphology and anatomic localization of renal microneoplasms and proximal tubule dysplasias induced by four different estrogens in the hamster. Cancer Res (1990) 0.81
Tissue inhibitors of metalloproteinases: evolution, structure and function. Biochim Biophys Acta (2000) 5.39
Somatic mutations of the APC gene in colorectal tumors: mutation cluster region in the APC gene. Hum Mol Genet (1992) 5.14
Germ-line mutations of the APC gene in 53 familial adenomatous polyposis patients. Proc Natl Acad Sci U S A (1992) 4.13
Purification and cloning of aggrecanase-1: a member of the ADAMTS family of proteins. Science (1999) 3.22
Activation of matrix metalloproteinase-9 (MMP-9) via a converging plasmin/stromelysin-1 cascade enhances tumor cell invasion. J Biol Chem (1999) 3.06
A metalloproteinase from human rheumatoid synovial fibroblasts that digests connective tissue matrix components. Purification and characterization. J Biol Chem (1986) 2.65
ATP-sensitive K+ channel in the mitochondrial inner membrane. Nature (1991) 2.60
TIMP-3 is a potent inhibitor of aggrecanase 1 (ADAM-TS4) and aggrecanase 2 (ADAM-TS5). J Biol Chem (2001) 2.58
Matrix metalloproteinase 3 (stromelysin) activates the precursor for the human matrix metalloproteinase 9. J Biol Chem (1992) 2.43
Cloning and characterization of ADAMTS11, an aggrecanase from the ADAMTS family. J Biol Chem (1999) 2.33
Mechanism of inhibition of the human matrix metalloproteinase stromelysin-1 by TIMP-1. Nature (1997) 2.17
Matrix metalloproteinase 2 from human rheumatoid synovial fibroblasts. Purification and activation of the precursor and enzymic properties. Eur J Biochem (1990) 2.13
Mechanisms of activation of tissue procollagenase by matrix metalloproteinase 3 (stromelysin). Biochemistry (1990) 2.06
The amount and proteolytic content of vesicles shed by human cancer cell lines correlates with their in vitro invasiveness. Anticancer Res (1998) 1.94
Matrix metalloproteinase-2 production and its binding to the matrix are increased in abdominal aortic aneurysms. Arterioscler Thromb Vasc Biol (1998) 1.90
Regulation of matrix metalloproteinases (MMP-2, -3, -9, and -13) by interleukin-1 and interleukin-6 in mouse calvaria: association of MMP induction with bone resorption. Endocrinology (1998) 1.75
Localization of matrix metalloproteinase 3 (stromelysin) in osteoarthritic cartilage and synovium. Lab Invest (1992) 1.74
Degradation of chromosomal DNA during apoptosis. Cell Death Differ (2003) 1.73
Immunolocalization of matrix metalloproteinase 3 (stromelysin) in rheumatoid synovioblasts (B cells): correlation with rheumatoid arthritis. Ann Rheum Dis (1989) 1.71
Degradation of interleukin 1beta by matrix metalloproteinases. J Biol Chem (1996) 1.69
Frequent somatic mutations of the APC gene in human pancreatic cancer. Cancer Res (1992) 1.55
The complete primary structure of human matrix metalloproteinase-3. Identity with stromelysin. J Biol Chem (1988) 1.54
Human plasma kallikrein. A rapid purification method with high yield. Biochem J (1981) 1.53
Nor-binaltorphimine: a potent and selective kappa-opioid receptor antagonist with long-lasting activity in vivo. Arch Int Pharmacodyn Ther (1992) 1.51
Detection of 12 germ-line mutations in the adenomatous polyposis coli gene by polymerase chain reaction. Gastroenterology (1993) 1.49
The APC gene, responsible for familial adenomatous polyposis, is mutated in human gastric cancer. Cancer Res (1992) 1.47
Urokinase plasminogen activator and gelatinases are associated with membrane vesicles shed by human HT1080 fibrosarcoma cells. J Biol Chem (1997) 1.45
Structural properties of matrix metalloproteinases. Cell Mol Life Sci (1999) 1.43
Synovial procollagenase activation by human mast cell tryptase dependence upon matrix metalloproteinase 3 activation. J Clin Invest (1989) 1.42
Purification of an endogenous activator of procollagenase from rabbit synovial fibroblast culture medium. J Biol Chem (1983) 1.42
Steps involved in activation of the pro-matrix metalloproteinase 9 (progelatinase B)-tissue inhibitor of metalloproteinases-1 complex by 4-aminophenylmercuric acetate and proteinases. J Biol Chem (1995) 1.42
Inactivation of tissue inhibitor of metalloproteinases by neutrophil elastase and other serine proteinases. FEBS Lett (1988) 1.39
Inhibition of matrix metalloproteinases prevents allergen-induced airway inflammation in a murine model of asthma. J Immunol (1999) 1.38
Hydrolysis of triple-helical collagen peptide models by matrix metalloproteinases. J Biol Chem (2000) 1.35
Selective localization of matrix metalloproteinase 9, beta1 integrins, and human lymphocyte antigen class I molecules on membrane vesicles shed by 8701-BC breast carcinoma cells. Cancer Res (1998) 1.33
Identification of the (183)RWTNNFREY(191) region as a critical segment of matrix metalloproteinase 1 for the expression of collagenolytic activity. J Biol Chem (2000) 1.32
Matrix metalloproteinases degrade insulin-like growth factor-binding protein-3 in dermal fibroblast cultures. J Biol Chem (1994) 1.32
The precursor of a metalloendopeptidase from human rheumatoid synovial fibroblasts. Purification and mechanisms of activation by endopeptidases and 4-aminophenylmercuric acetate. Biochem J (1988) 1.30
An improved assay for proteases and polysaccharidases employing a cartilage proteoglycan substrate entrapped in polyacrylamide particles. Anal Biochem (1980) 1.29
Continuously recording fluorescent assays optimized for five human matrix metalloproteinases. Anal Biochem (1991) 1.28
Purification and characterization of matrix metalloproteinase 9 from U937 monocytic leukaemia and HT1080 fibrosarcoma cells. Biochem J (1992) 1.27
Application of the message-address concept in the design of highly potent and selective non-peptide delta opioid receptor antagonists. J Med Chem (1988) 1.25
Evidence that human rheumatoid synovial matrix metalloproteinase 3 is an endogenous activator of procollagenase. Arch Biochem Biophys (1988) 1.24
Identification of matrix metalloproteinases 3 (stromelysin-1) and 9 (gelatinase B) in abdominal aortic aneurysm. Arterioscler Thromb (1994) 1.23
Nonenzymatic glycation of type IV collagen and matrix metalloproteinase susceptibility. Kidney Int (1997) 1.23
A precursor form of latent collagenase produced in a cell-free system with mRNA from rabbit synovial cells. J Biol Chem (1981) 1.22
A novel host/tumor cell interaction activates matrix metalloproteinase 1 and mediates invasion through type I collagen. J Biol Chem (1999) 1.22
Recognition and catabolism of synthetic heterotrimeric collagen peptides by matrix metalloproteinases. Chem Biol (2000) 1.21
Biosynthesis and secretion of procollagenase by rabbit synovial fibroblasts. Inhibition of procollagenase secretion by monensin and evidence for glycosylation of procollagenase. Biochem J (1983) 1.21
Preferential inactivation of tissue inhibitor of metalloproteinases-1 that is bound to the precursor of matrix metalloproteinase 9 (progelatinase B) by human neutrophil elastase. J Biol Chem (1995) 1.20
Purification of the neutral proteoglycan-degrading metalloproteinase from human articular cartilage tissue and its identification as stromelysin matrix metalloproteinase-3. Biochem J (1989) 1.20
Opioid-induced second window of cardioprotection: potential role of mitochondrial KATP channels. Circ Res (1999) 1.20
Progressive polyarthritis induced in BALB/c mice by aggrecan from normal and osteoarthritic human cartilage. Arthritis Rheum (1998) 1.19
Kinetic analysis of matrix metalloproteinase activity using fluorogenic triple-helical substrates. Biochemistry (2001) 1.19
Cancer resistance genes in mice: models for the study of tumour modifiers. Trends Genet (1998) 1.19
Insights into MMP-TIMP interactions. Ann N Y Acad Sci (1999) 1.18
Expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in the mouse uterus during the peri-implantation period. Dev Genet (1997) 1.18
Plasma membrane-bound tissue inhibitor of metalloproteinases (TIMP)-2 specifically inhibits matrix metalloproteinase 2 (gelatinase A) activated on the cell surface. J Biol Chem (1998) 1.17
Folding and characterization of the amino-terminal domain of human tissue inhibitor of metalloproteinases-1 (TIMP-1) expressed at high yield in E. coli. FEBS Lett (1996) 1.16
Genetic diagnosis identifies occult lymph node metastases undetectable by the histopathological method. Cancer Res (1994) 1.16
Co-culture of human breast adenocarcinoma MCF-7 cells and human dermal fibroblasts enhances the production of matrix metalloproteinases 1, 2 and 3 in fibroblasts. Br J Cancer (1995) 1.14
Production of tissue collagenase (matrix metalloproteinase 1) by human aortic smooth muscle cells in response to platelet-derived growth factor. Atherosclerosis (1991) 1.13
The mitogen-activated protein kinase and JAK-STAT signaling pathways are required for an oncostatin M-responsive element-mediated activation of matrix metalloproteinase 1 gene expression. J Biol Chem (1997) 1.13
Identification of plasma kallikrein as an activator of latent collagenase in rheumatoid synovial fluid. Biochim Biophys Acta (1982) 1.13
Opioid-induced cardioprotection against myocardial infarction and arrhythmias: mitochondrial versus sarcolemmal ATP-sensitive potassium channels. J Pharmacol Exp Ther (2000) 1.11
Elevated levels of soluble CD163 in sera and fluids from rheumatoid arthritis patients and inhibition of the shedding of CD163 by TIMP-3. Clin Exp Immunol (2002) 1.08
Mutational study of the amino-terminal domain of human tissue inhibitor of metalloproteinases 1 (TIMP-1) locates an inhibitory region for matrix metalloproteinases. J Biol Chem (1997) 1.08
Chemokines induce eosinophil degranulation through CCR-3. J Allergy Clin Immunol (2000) 1.08
Human breast carcinoma cells cultured in the presence of serum shed membrane vesicles rich in gelatinolytic activities. J Submicrosc Cytol Pathol (1994) 1.08
Alternative splicing of the NF2 gene and its mutation analysis of breast and colorectal cancers. Hum Mol Genet (1994) 1.07
Stimulation of angiogenesis through cathepsin B inactivation of the tissue inhibitors of matrix metalloproteinases. FEBS Lett (1999) 1.07
Activation of proMMP-9 by a plasmin/MMP-3 cascade in a tumor cell model. Regulation by tissue inhibitors of metalloproteinases. Ann N Y Acad Sci (1999) 1.06
Matrix metalloproteinases as insulin-like growth factor binding protein-degrading proteinases. Prog Growth Factor Res (1995) 1.05
Norbinaltorphimine, a selective kappa-opioid receptor antagonist, induces an itch-associated response in mice. Eur J Pharmacol (2001) 1.05
Multiple forms of the APC gene transcripts and their tissue-specific expression. Hum Mol Genet (1993) 1.05
The role of mu- and kappa-opioid receptors in cocaine-induced conditioned place preference. Jpn J Pharmacol (1992) 1.05
Characterization of an immunosuppressive factor derived from colon cancer cells. J Immunol (1987) 1.04
Increased level of translatable collagenase messenger ribonucleic acid in rabbit synovial fibroblasts treated with phorbol myristate acetate or crystals of monosodium urate monohydrate. Biochemistry (1982) 1.04
Epithelial carcinogenesis in the mouse: correlating the genetics and the biology. Philos Trans R Soc Lond B Biol Sci (1998) 1.03
Early activation signal transduction pathways of Th1 and Th2 cell clones stimulated with anti-CD3. Roles of protein tyrosine kinases in the signal for IL-2 and IL-4 production. J Immunol (1995) 1.03
Salmonella virchow infection in an infant transmitted by household dogs. J Vet Med Sci (2000) 1.03
Differential expression of gelatinase B (MMP-9) and stromelysin-1 (MMP-3) by rheumatoid synovial cells in vitro and in vivo. Rheumatol Int (1993) 1.02
A novel hydra matrix metalloproteinase (HMMP) functions in extracellular matrix degradation, morphogenesis and the maintenance of differentiated cells in the foot process. Development (2000) 1.02
Only one pharmacophore is required for the kappa opioid antagonist selectivity of norbinaltorphimine. J Med Chem (1988) 1.02
Matrix metalloproteinases and their inhibitors in human vitreous. Invest Ophthalmol Vis Sci (1998) 1.02
Residue 2 of TIMP-1 is a major determinant of affinity and specificity for matrix metalloproteinases but effects of substitutions do not correlate with those of the corresponding P1' residue of substrate. J Biol Chem (1999) 1.02
Importance of matrix metalloproteinases in human trophoblast invasion. Early Pregnancy (1995) 1.02
Induction of interleukin-12 p40 transcript by CD40 ligation via activation of nuclear factor-kappaB. Eur J Immunol (1997) 1.02
Expression of human pro-matrix metalloproteinase 3 that lacks the N-terminal 34 residues in Escherichia coli: autoactivation and interaction with tissue inhibitor of metalloproteinase 1 (TIMP-1). Biol Chem (1998) 1.01
Production of matrix metalloproteinases 2 and 3 (stromelysin) by stromal cells of giant cell tumor of bone. Am J Pathol (1992) 1.00
Matrix metalloproteinase production by cultured human endometrial stromal cells: identification of interstitial collagenase, gelatinase-A, gelatinase-B, and stromelysin-1 and their differential regulation by interleukin-1 alpha and tumor necrosis factor-alpha. J Clin Endocrinol Metab (1994) 1.00
Buprenorphine exerts its antinociceptive activity via mu 1-opioid receptors. Life Sci (1995) 1.00
TAN-67, a delta 1-opioid receptor agonist, reduces infarct size via activation of Gi/o proteins and KATP channels. Am J Physiol (1998) 1.00
Immunohistochemical demonstration of collagenase and tissue inhibitor of metalloproteinases (TIMP) in synovial lining cells of rheumatoid synovium. Virchows Arch B Cell Pathol Incl Mol Pathol (1990) 0.99
Mutations of the adenomatous polyposis coli gene in familial polyposis coli patients and sporadic colorectal tumors. Princess Takamatsu Symp (1991) 0.99
Runt-related transcription factor 2 (RUNX2) inhibits p53-dependent apoptosis through the collaboration with HDAC6 in response to DNA damage. Cell Death Dis (2013) 0.99
MMPs are IGFBP-degrading proteinases: implications for cell proliferation and tissue growth. Ann N Y Acad Sci (1999) 0.99